Search our team at AdventHealth Research Institute
-
NCT04998747
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchParticipants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn...
-
NCT05346835
68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT05948865
CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into...
-
NCT04669899
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchA medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening...